HomeCompareMENB vs MRK

MENB vs MRK: Dividend Comparison 2026

MENB yields 20000000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MENB wins by $4.875981653489057e+49M in total portfolio value
10 years
MENB
MENB
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full MENB calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — MENB vs MRK

📍 MENB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMENBMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MENB + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MENB pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MENB
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MENB beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MENB + MRK for your $10,000?

MENB: 50%MRK: 50%
100% MRK50/50100% MENB
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MENB
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MENB buys
0
MRK buys
0
No recent congressional trades found for MENB or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMENBMRK
Forward yield20000000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.875981653489057e+49M$56.8K
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$4.875978515990276e+49M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MENB vs MRK ($10,000, DRIP)

YearMENB PortfolioMENB Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,206$366.19+$2000.00MMENB
2$373,835,915,712,384$373,833,775,700,934.50$12,650$502.35+$373835915.70MMENB
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$14,407$694.19+$65304953364964.95MMENB
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$16,585$967.82+$10661728832755499008.00MMENB
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$19,342$1,363.89+$1.626767783781495e+24MMENB
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$22,913$1,947.19+$2.319743300546251e+29MMENB
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$27,662$2,823.89+$3.0915106403922057e+34MMENB
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$34,159$4,173.35+$3.8505079858392777e+39MMENB
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$43,337$6,308.80+$4.4821026103531426e+44MMENB
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$4.875981653489057e+49MMENB

MENB vs MRK: Complete Analysis 2026

MENBStock

Mendocino Brewing Company, Inc., together with its subsidiaries, engages in the brewing, production, and sale of beer and malt beverages in the United States, Canada, and Europe. It operates through two segments, the North American Territory and the Foreign Territory. The company produces and markets craft beers primarily under the Red Tail Ale, Blue Heron Pale Ale, Black Hawk Stout, Eye of the Hawk Select Ale, and White Hawk Original IPA. It also owns and operates brewpub and gift store in Ukiah, California; brews its products for various other brands on contract basis; and distributes alcoholic beverages, primarily under Kingfisher Premium Lager brand in the United Kingdom and Europe. The company sells its products through wholesale distributors to consumers at supermarkets, warehouse stores, liquor stores, taverns and bars, restaurants, and convenience stores in North America; Indian restaurants by restaurant trade distributors, as well as through supermarkets, liquor stores, and licensed shops and convenience stores in the European Union;; and through provincial liquor boards and independent distributors in Canada. Mendocino Brewing Company, Inc. was founded in 1982 and is based in Ukiah, California.

Full MENB Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MENB vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MENB vs SCHDMENB vs JEPIMENB vs OMENB vs KOMENB vs MAINMENB vs JNJMENB vs ABBVMENB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.